Abiopharma

Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025

Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy

UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial

Vericel Reports Third Quarter 2025 Financial Results

Cronos Group Reports 2025 Third Quarter Results

Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs

Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Evaxion announces business update and third quarter 2025 financial results

Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025